At a glance
ClinicalIndex Comparison RecordN/ACompleted· 140 enrolled
Drug / intervention
Meperidine +1 moredrug
Likely dose
Meperidine 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Meperidine as the Single Sedative Agent During Esophagogastroduodenoscopy, a Double-blind, Randomized Controlled Study
In Brief
A clinical study evaluating Meperidine and normal saline for Esophagogastroduodenoscopy. Completed, enrolled 140 participants across 1 site.
Detailed Summary
Upper endoscopy is uncomfortable for most patients. Meperidine has both sedative and analgesic effects, so its use may be helpful for patients receiving upper endoscopy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophagogastroduodenoscopy
CountriesTaiwan
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2011
Primary CompletionFeb 2012
First PostedMar 2012
TodayJul 2026
First PostedMar 8, 2012
Enrollment StartJun 1, 2011
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 14.3 years ago
Interventions
Meperidinedrug
intramuscular, 25 mg, 5 to 10 minutes before EGD
normal salinedrug
25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD